AI Article Synopsis
- Proteolysis-targeting chimeras (PROTACs) are innovative molecules designed to promote the degradation of specific proteins by leveraging the body's natural protein breakdown systems.
- This study introduces a method to create covalent ligands that target the Von Hippel-Lindau (VHL) protein, specifically binding to the HIF1α binding site.
- The successful integration of these ligands into bifunctional degraders allows for the targeted degradation of proteins like BRD4 and the androgen receptor, broadening the potential applications of PROTACs in therapy.
Article Abstract
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that have emerged as a therapeutic modality to induce targeted protein degradation (TPD) by harnessing cellular proteolytic degradation machinery. PROTACs which ligand the E3 ligase in a covalent manner have attracted intense interest; however, covalent PROTACs with a broad protein of interest (POI) scope have proven challenging to discover by design. Here, we report the structure-guided design and optimization of Von Hippel-Lindau (VHL) protein-targeted sulfonyl fluorides which covalently bind Ser110 in the HIF1α binding site. We demonstrate that their incorporation in bifunctional degraders induces targeted protein degradation of BRD4 or the androgen receptor without further linker optimization. Our study discloses the first covalent VHL ligands which can be implemented directly in bifunctional degrader design, expanding the substrate scope of covalent E3 ligase PROTACs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982999 | PMC |
| http://dx.doi.org/10.1021/acs.jmedchem.3c02123 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!